-
Milestone Pharmaceuticals NasdaqGS:MIST Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Location: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, H4M 2X6, Canada | Website: https://www.milestonepharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
111.1M
Cash
55.96M
Avg Qtr Burn
-8.467M
Short % of Float
4.16%
Insider Ownership
4.71%
Institutional Own.
22.25%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
CARDAMYST (Etripamil) (calcium channel blocker) Details Paroxysmal supraventricular tachycardia | NDA Resubmission | |
Etripamil (calcium channel blocker) Details Atrial fibrillation | Phase 3 Initiation | |
Etripamil (calcium channel blocker) Details Angina, Coronary artery disease | Failed Discontinued |